Long-term renal function after treatment for malignant germ-cell tumours

被引:91
作者
Fosså, SD
Aass, N
Winderen, M
Börmer, OP
Olsen, DR
机构
[1] Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, N-0310 Oslo, Norway
[2] Norwegian Radium Hosp, Dept Nucl Med, N-0310 Oslo, Norway
[3] Norwegian Radium Hosp, Dept Med Phys, N-0310 Oslo, Norway
[4] Norwegian Radium Hosp, Cent Lab, N-0310 Oslo, Norway
关键词
long-term renal function; testicular cancer; treatment;
D O I
10.1093/annonc/mdf048
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate prospectively renal function in patients with malignant germ-cell tumours (MGCTs) >10 years after retroperitoneal lymph node dissection alone (RPLND), radiotherapy alone (RAD) or different schedules of cisplatin-based chemotherapy with or without surgery/radiotherapy (CHEM). Patients and methods: In 85 patients, three groups were identified: RPLND, 14; RAD, 18; CHEM, 53, with subdivision of the latter group according to the cumulative cisplatin dose or the additional use of radiotherapy. Renal function was determined by (134)Iodine Hippuran clearance or (99)m DTPA glomerular filtration rate, and was assessed before treatment and four times during 14 years of follow-up. A value of <70% of the upper limit of the normal range identified impaired renal function. Results: Twenty-five patients displayed long-term impaired renal function, 23 of them from the RAD or CHEM group. In the RAD group, renal function decreased by 8%, whereas a 14% reduction of renal function was observed in the CHEM group. In the CHEM group the cumulative dose of cisplatin, and in the RAD group the age at treatment, were associated with impairment of renal function. Combining all patients, age at treatment and the type of treatment were associated with impaired renal function. Conclusions: In 20-30% of the patients with germ-cell tumour, standard radiotherapy and chemotherapy strategies are followed by long-term subclinical impaired renal function. These findings support current intentions to avoid overtreatment with these treatment modalities.
引用
收藏
页码:222 / 228
页数:7
相关论文
共 27 条
[1]   RENAL-FUNCTION RELATED TO DIFFERENT TREATMENT MODALITIES FOR MALIGNANT GERM-CELL TUMORS [J].
AASS, N ;
FOSSA, SD ;
AAS, M ;
LINDEGAARD, MW .
BRITISH JOURNAL OF CANCER, 1990, 62 (05) :842-846
[2]   Evaluation of long-term toxicity after chemotherapy for testicular cancer [J].
Bokemeyer, C ;
Berger, CC ;
Kuczyk, MA ;
Schmoll, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (11) :2923-2932
[3]   LACK OF LATE TOXICITY IN PATIENTS TREATED WITH CISPLATIN-CONTAINING COMBINATION CHEMOTHERAPY FOR METASTATIC TESTICULAR CANCER [J].
BOYER, M ;
RAGHAVAN, D ;
HARRIS, PJ ;
LIETCH, J ;
BLEASEL, A ;
WALSH, JC ;
ANDERSON, S ;
TSANG, CS .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) :21-26
[4]  
Cappelen Tone, 1999, Tidsskrift for den Norske Laegeforening, V119, P521
[5]   Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer:: A randomized study of the European organization for research and treatment of cancer genitourinary tract cancer cooperative group and the medical research council [J].
de Wit, R ;
Roberts, JT ;
Wilkinson, PM ;
de Mulder, PHM ;
Mead, GM ;
Fosså, SD ;
Cook, P ;
de Prijck, L ;
Stenning, S ;
Collette, L .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1629-1640
[6]   RADIATION-INJURY IN THE HUMAN KIDNEY - A PROSPECTIVE ANALYSIS USING SPECIFIC SCINTIGRAPHIC AND BIOCHEMICAL END-POINTS [J].
DEWIT, L ;
ANNINGA, JK ;
HOEFNAGEL, CA ;
NOOIJEN, WJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (04) :977-983
[7]   RADIOTHERAPY FOR TESTICULAR SEMINOMA STAGE-I - TREATMENT RESULTS AND LONG-TERM POST-IRRADIATION MORBIDITY IN 365 PATIENTS [J].
FOSSA, SD ;
AASS, N ;
KAALHUS, O .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 16 (02) :383-388
[8]  
Gerl A, 2000, ACTA ONCOL, V39, P519
[9]   LONG-TERM EFFECTS ON RENAL-FUNCTION AND BLOOD-PRESSURE OF TREATMENT WITH CISPLATIN, VINBLASTINE, AND BLEOMYCIN IN PATIENTS WITH GERM-CELL CANCER [J].
HANSEN, SW ;
GROTH, S ;
DAUGAARD, G ;
ROSSING, N ;
RORTH, M .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (11) :1728-1731
[10]  
HUDDART RA, 2000, ASCO P, V19, pA331